Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Biopharma has announced a $230 million share buyback program and a cash infusion from Moderna to advance its potential hepatitis B cure. The company aims to submit a New Drug Application for its lead candidate, AB-729, in the first half of 2023.

The buyback program, valued at approximately 10% of Arbutus' outstanding shares, is expected to be completed by the end of 2023. Moderna's investment of $100 million will support the development of AB-729 and Arbutus' other pipeline candidates.